

Nghia H Nguyen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4331550/publications.pdf>

Version: 2024-02-01

42
papers

812
citations

516561

16
h-index

552653

26
g-index

42
all docs

42
docs citations

42
times ranked

1127
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness and Safety of Biologic Therapy in Hispanic Vs Non-Hispanic Patients With Inflammatory Bowel Diseases: A CA-IBD Cohort Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 173-181.e5.	2.4	4
2	Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 364-372.	0.9	28
3	Patient-Reported Outcomes and Risk of Hospitalization and Readmission in Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2039-2048.	1.1	5
4	Systematic Review and Meta-Analysis: Risk of Hospitalization in Patients with Ulcerative Colitis and Crohn's Disease in Population-Based Cohort Studies. <i>Digestive Diseases and Sciences</i> , 2022, 67, 2451-2461.	1.1	12
5	Machine Learning-based Prediction Models for Diagnosis and Prognosis in Inflammatory Bowel Diseases: A Systematic Review. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 398-413.	0.6	11
6	Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review. <i>American Journal of Gastroenterology</i> , 2022, 117, 78-97.	0.2	22
7	Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Patients With Inflammatory Bowel Disease on Immune-Modulating Therapies. <i>Clinical and Translational Gastroenterology</i> , 2022, 13, e00484.	1.3	8
8	Impact of Comorbid Psychiatric Disorders on Healthcare Utilization in Patients with Inflammatory Bowel Disease: A Nationally Representative Cohort Study. <i>Digestive Diseases and Sciences</i> , 2022, , .	1.1	3
9	National Estimates of Financial Hardship From Medical Bills and Cost-related Medication Nonadherence in Patients With Inflammatory Bowel Diseases in the United States. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1068-1078.	0.9	12
10	Frailty Is Independently Associated with Mortality and Readmission in Hospitalized Patients with Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2054-2063.e14.	2.4	52
11	Baseline Clearance of Infliximab Is Associated With Requirement for Colectomy in Patients With Acute Severe Ulcerative Colitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 511-518.e6.	2.4	28
12	Prevalence and Effects of Food Insecurity and Social Support on Financial Toxicity in and Healthcare Use by Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1377-1386.e5.	2.4	17
13	Abdominal free fluid in acute pancreatitis predicts necrotizing pancreatitis and organ failure. <i>Annals of Gastroenterology</i> , 2021, 34, 872-878.	0.4	3
14	Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996-2016. <i>American Journal of Gastroenterology</i> , 2021, 116, 2060-2067.	0.2	19
15	Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States. <i>Hepatology</i> , 2021, 74, 1509-1522.	3.6	9
16	Cost-Related Nonadherence to Medications Among US Adults With Chronic Liver Diseases. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2639-2650.	1.4	13
17	Case-control study of the association of chronic acid suppression and social determinants of health with COVID-19 infection. <i>Scientific Reports</i> , 2021, 11, 20987.	1.6	1
18	Positioning Therapies in the Management of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1268-1279.	2.4	33

#	ARTICLE	IF	CITATIONS
19	Rate of Risk Factors for and Interventions to Reduce Hospital Readmission in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1939-1948.e7.	2.4	22
20	Biomarkers are associated with clinical and endoscopic outcomes with vedolizumab treatment in Crohn's disease. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482097121.	1.4	7
21	Incorporating Fecal Calprotectin Into Clinical Practice for Patients With Moderate-to-Severely Active Ulcerative Colitis Treated With Biologics or Small-Molecule Inhibitors. <i>American Journal of Gastroenterology</i> , 2020, 115, 885-894.	0.2	15
22	Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir: A Propensity Score-Matched Study. <i>Journal of Infectious Diseases</i> , 2019, 219, 10-18.	1.9	72
23	Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. <i>The Cochrane Library</i> , 2019, 5, CD001176.	1.5	16
24	Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. <i>The Cochrane Library</i> , 2019, 11, CD001176.	1.5	15
25	Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases. <i>American Journal of Gastroenterology</i> , 2019, 114, 630-639.	0.2	53
26	Comparison of Multiplex Gastrointestinal Pathogen Panel and Conventional Stool Testing for Evaluation of Diarrhea in Patients with Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , 2019, 64, 382-390.	1.1	22
27	Obesity Is Independently Associated With Higher Annual Burden and Costs of Hospitalization in Patients With Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 709-718.e7.	2.4	34
28	Annual Burden and Costs of Hospitalization for High-Need, High-Cost Patients With Chronic Gastrointestinal and Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1284-1292.e30.	2.4	51
29	Infections and Cardiovascular Complications are Common Causes for Hospitalization in Older Patients with Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 916-923.	0.9	27
30	Heart Failure With Recovered Ejection Fraction in African Americans: Results From the African-American Heart Failure Trial. <i>Journal of Cardiac Failure</i> , 2018, 24, 303-309.	0.7	16
31	Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 742-753.	3.7	40
32	A Primer on Systematic Reviews and Meta-Analyses. <i>Seminars in Liver Disease</i> , 2018, 38, 103-111.	1.8	9
33	Tolerability and effectiveness of sofosbuvir and simeprevir in the post-transplant setting: systematic review and meta-analysis. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000066.	1.1	15
34	Effects of Cirrhosis on Short-term and Long-term Survival of Patients With Hepatitis B-related Hepatocellular Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 887-895.e1.	2.4	24
35	Reduced Myelination and Increased Glia Reactivity Resulting from Severe Neonatal Hyperbilirubinemia. <i>Molecular Pharmacology</i> , 2016, 89, 84-93.	1.0	29
36	Re-treatment of patients with chronic hepatitis C virus genotype 4 infection with pegylated interferon and ribavirin: a meta-analysis. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000057.	1.1	0

#	ARTICLE	IF	CITATIONS
37	Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: a meta-analysis. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000049.	1.1	13
38	Long-term follow-up and suboptimal treatment rates of treatment-eligible chronic hepatitis B patients in diverse practice settings: a gap in linkage to care. <i>BMJ Open Gastroenterology</i> , 2015, 2, e000060.	1.1	14
39	Safety and efficacy of entecavir in adefovir-experienced patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 43-50.	1.4	7
40	Current Treatment Options in Patients with Hepatitis C Virus Genotype 6. <i>Gastroenterology Clinics of North America</i> , 2015, 44, 871-881.	1.0	6
41	Meta-analysis of patients with hepatitis C virus genotype 6: 48 weeks with pegylated interferon and ribavirin is superior to 24 weeks. <i>Hepatology International</i> , 2014, 8, 540-549.	1.9	6
42	Treatment Eligibility of Patients With Chronic Hepatitis B Initially Ineligible for Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 565-571.	2.4	19